The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: Critical evaluation and recommendations for future studies
- 1 May 1992
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 3 (5) , 339-348
- https://doi.org/10.1093/oxfordjournals.annonc.a058203
Abstract
Phase I studies requiring multiple dose escalation steps have led to the development of pharmacokinetically guided dose escalation (PGDE) strategies to expedite the conduct of early clinical trials. This article critically reviews PGDE strategies for a number of new anticancer agents including amphethinile, brequinar sodium, iodo-doxorubicin, the anthrapyrazoles (DuP 941, DuP 942 and DuP 937), rhizoxin, and aphidicolin glycinate. The benefits and problems associated with PGDE are examined. Recommendations are made for the optimal deployment of pharmacological information in future phase I studies.Keywords
This publication has 21 references indexed in Scilit:
- New anthracycline derivatives: What for?European Journal of Cancer and Clinical Oncology, 1991
- Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignanciesCancer Chemotherapy and Pharmacology, 1990
- Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug DevelopmentJNCI Journal of the National Cancer Institute, 1990
- General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe : Joint Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC) and the Cancer Research Campaign (CRC)European Journal of Cancer and Clinical Oncology, 1990
- Phase I clinical studies with cytotoxic drugs: pharmacokinetic and pharmacodynamic considerationsBritish Journal of Cancer, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- A phase I and pharmacokinetic study of amphethinileBritish Journal of Cancer, 1988
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987
- In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles)Biochemical Pharmacology, 1985
- Mouse and large-animal toxicology studies of twelve antitumor agents: Relevance to starting dose for Phase I clinical trialsCancer Chemotherapy and Pharmacology, 1979